A green Mediterranean pattern combining walnuts, green tea, Mankai, and greater restriction of red and processed meat,
does it really help with Reduced intrahepatic fat by MRS over 18 months in adults with abdominal obesity or dyslipidemia?
research showsGrade C. In the 294-person DIRECT-PLUS trial, proportional liver-fat reductions were -38.9% with green-MED, -19.6% with conventional MED, and -12.2% with healthy-diet guidance. The weight-loss-adjusted green-MED versus MED comparison was significant at P=.035, but the standardized effect was small and only 78% of randomized participants had eligible follow-up MRS. The result applies to the dietary package, not green tea or Mankai alone.
ads claimClaims that Mankai removes 39% of liver fat or that green tea treats fatty liver misattribute a bundled dietary trial to a single ingredient.
Useful facts when choosing a product
- The intervention bundled several foods and meat restriction.
- Both Mediterranean groups received walnuts and physical-activity guidance.
- Intrahepatic fat was measured by proton MRS.
What the research actually shows
Adults with abdominal obesity or dyslipidemia were randomized among healthy guidance, MED, and green-MED, all with physical activity. Both MED arms received 28 g/day walnuts; green-MED added 3-4 cups/day green tea, 100 g/day frozen Mankai, and greater red and processed meat restriction. Eligible MRS was available for 78% at 18 months.
Why this is classified as C (46)
A significant long-duration surrogate difference is offset by a small standardized effect and more than 15% missing follow-up MRS, giving C with 46 points.
Counterpoint. An 18-month trial with a weight-adjusted difference is stronger than many short nutrition studies.
Rejudgment record. Codex full-text, registry, and scoring cross-check — Applied the small standardized weight-adjusted green-MED versus MED effect at P=.035, surrogate endpoint, 78% eligible follow-up MRS, mixed funding interests, and single-trial evidence
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E~ | Statistically positive but below the threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| 18-month intrahepatic-fat reduction from the bundled green-MED pattern | C | Weight-adjusted P=.035 versus conventional MED. |
| Liver-fat reduction from Mankai or green tea alone | ? | The trial did not isolate individual component effects. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Three-arm 18-month randomized lifestyle trial | 78 | German, Israeli, and EU public support plus California Walnut Commission funding; PI disclosed Hinoman advisory role; funders reported no role in design or analysis | 18-month change in intrahepatic fat measured by proton MRS | Green-MED -38.9%, MED -19.6%, HDG -12.2%; weight-adjusted green-MED vs MED P=.035 | Positive long-term surrogate evidence with bundled intervention and imaging missingness |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-07).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-07 · Corrections: none
Cite this verdict
[Chamgap] Green Mediterranean Diet for 18-Month Reduction in MRS Intrahepatic Fat — Evidence Grade C·46. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/green-mediterranean-diet-intrahepatic-fat-direct-plus/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.